1 / 9

Drug Stores: Walmart

Drug Stores: Walmart. Eric Biro. Date of Value/Mid-Year Adjustments. Data used in valuation from F/S released 1/31/2013 Multiplied enterprise value by to bring value to today Expecting new financials sometime this week Adjusted timing of discounting to midyear

asabi
Télécharger la présentation

Drug Stores: Walmart

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Stores: Walmart Eric Biro

  2. Date of Value/Mid-Year Adjustments • Data used in valuation from F/S released 1/31/2013 • Multiplied enterprise value by to bring value to today • Expecting new financials sometime this week • Adjusted timing of discounting to midyear • Multiplied enterprise value at 3/31/2014 by to more realistically show cash flows • Adjustments raised valuation by $54 billion

  3. Market Value of Debt Estimate • By definition:

  4. Value of Equity Share Estimate - Debt

  5. Sensitivity Analysis: WACC/Terminal Growth • Valuation shows Walmart as a strong buy compared to market’s value in all but the worst of situations

  6. Analyst Forecasts • Earnings • $5.76 - Consensus (2016) • $5.31 - NASDAQ (2016) • $5.81/$6.45 - 4-traders (2016/2017) • $7.00 - Value Line (2017) • Dividends • $1.98, $2.19 - 4-traders (2015/2016) • $2.50 - Value Line (2017) • Target prices • $105 - Value Line (2017) • $82 - Consensus (2015) • Sales Growth • 4.00% - Consensus (2014) • 4.50% - Fin. Times (2014-5) • 2.92%/4.03%/4.41% - 4-traders (2014-6)

  7. Value of Equity Share Estimates - Analyst • Dividend discount model • Uses projected dividends to compute a target price per share • Target prices • $105 - Value Line (2017) • $82 - Consensus (2015)

  8. Value of Equity Share Estimates - Analyst • Residual Income • Bases target price off residual earnings () • Target prices • $105 - Value Line (2017) • $82 - Consensus (2015)

  9. Takeaways • Lots of value is based on continuing estimates, which can swing valuation wildly depending on assumptions/model • 39% / 57% / 81% • Walmart appears undervalued by the market according to this valuation • Analysts have been downgrading the stock – how accurate is this? • Had issues calculating the long-term growth in residual income and earnings/sales

More Related